statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	756
SG - Singapore	213
CN - Cina	133
FI - Finlandia	87
IT - Italia	81
BR - Brasile	73
HK - Hong Kong	57
DE - Germania	47
BD - Bangladesh	46
VN - Vietnam	33
UA - Ucraina	27
CA - Canada	25
GB - Regno Unito	25
PL - Polonia	22
FR - Francia	20
TR - Turchia	17
RU - Federazione Russa	16
IN - India	11
NL - Olanda	11
IE - Irlanda	10
MX - Messico	8
JP - Giappone	7
ZA - Sudafrica	6
CZ - Repubblica Ceca	5
AR - Argentina	4
ES - Italia	4
TW - Taiwan	4
PK - Pakistan	3
AT - Austria	2
AZ - Azerbaigian	2
CR - Costa Rica	2
DZ - Algeria	2
GE - Georgia	2
ID - Indonesia	2
IQ - Iraq	2
IR - Iran	2
LT - Lituania	2
MA - Marocco	2
NO - Norvegia	2
PY - Paraguay	2
VE - Venezuela	2
AU - Australia	1
BE - Belgio	1
BO - Bolivia	1
CH - Svizzera	1
EC - Ecuador	1
EG - Egitto	1
ET - Etiopia	1
GM - Gambi	1
HN - Honduras	1
IL - Israele	1
JM - Giamaica	1
JO - Giordania	1
KZ - Kazakistan	1
LV - Lettonia	1
MN - Mongolia	1
MY - Malesia	1
NP - Nepal	1
PA - Panama	1
PR - Porto Rico	1
SA - Arabia Saudita	1
SE - Svezia	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
UZ - Uzbekistan	1
Totale	1.801

Nome	#
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	349
COVID-19 impact on consecutive neurological patients admitted to the emergency department	257
Where SUNCT Contacts TN: A Case Report	182
Un caso peculiare di ipertensione secondaria	125
Un caso peculiare di ipertensione arteriosa secondaria.	120
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study	117
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine	104
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine	97
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor	89
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination	83
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab	66
Photophobia and migraine outcome during treatment with galcanezumab	60
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination	59
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients	57
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation	56
Totale	1.821

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	7	0	0	0	0	0	0	0	0	0	0	0	7
2021/2022	54	2	19	0	0	0	2	4	2	4	4	6	11
2022/2023	62	5	4	1	3	5	11	0	12	13	2	2	4
2023/2024	75	4	1	10	5	1	19	0	1	12	1	13	8
2024/2025	402	8	0	4	62	27	29	32	30	48	39	70	53
2025/2026	943	76	90	45	113	89	87	169	42	58	58	42	74
Totale													1.821